“It’s déjà vu all over again” – Yogi Berra With Opening Day less than a month away, it seems only fitting to reference one of the most quoted personalities of our time to describe our analysis of the biotechnology sector in 2010. In this article, we review our favorable outlook for the industry, draw...
Read More »
Posts Tagged ‘ XNPT ’
Allos Therapeutics
ALTH
AMAG
AMAG Pharmaceuticals
American Society of Clinical Oncology
Amgen
AMGN
Amicus Therapeutics
AMLN
ASCO
Astellas Pharma
BIIB
Biogen Idec
biotech
biotechnology
BMY
CELG
Celgene
CEPH
Cephalon
CYCC
Cyclacel Pharmaceuticals
Dendreon
DNDN
FOLD
GENZ
GlaxoSmithKline
GSK
JNJ
Johnson & Johnson
life sciences
LLY
monoclonal antibodies
OSIR
Osiris Therapeutics
PFE
Pfizer
prostate cancer
Provenge
roche
Sanofi-Aventis
Seattle Genetics
SGEN
SNY
Soligenix
For Biotechnology in 2010, it’s Déjà vu All over Again
Ache-free Investment Opportunities in Neuropathic Pain
In the United States, up to 50 million people live with chronic pain, with the majority of these patients not satisfied with their current pain treatments. Pain is defined clinically as an unpleasant emotional experience resulting from real or potential tissue damage and is generally divided into two categories based on cause: Nociceptive pain,...
Read More »







